| ￥3300 | |
| Z05909-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 90% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | E.coli | ||||
| Theoretical Molecular Weight | 34.26 kDa | ||||
| Apparent Molecular Weight | The protein has a predicted MW of 34.26 kDa same as Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS, 150mM NaCl (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of TPM1, His, Human is greater than 90% as determined by SEC-HPLC. »
TPM1, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Tropomyosin-1 (TPM1), a widely expressed actin-binding protein, is downregulated in many tumors and associated with cancer progression. TPM1 overexpression in RCC cell lines can induce tumor cell apoptosis via the p53-mediated mitochondrial pathway. Further studies are needed to fully elucidate the potential of TPM1 as a candidate for RCC targeted therapy in the future. |
| Synonyms | C15orf13; TMSA; CMD1Y; CMH3; HTM-alpha; LVNC9 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
